ACC25: Ozempic shows its value in PAD

Novo Nordisk's Ozempic has been shown to improve waking distance and quality of life in people with type 2 diabetes (T2D) and peripheral artery disease (PAD), potentially adding yet another indication for the blockbuster GLP-1 agonist.